Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. reduced its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 43.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,326 shares of the biotechnology company’s stock after selling 10,884 shares during the period. Point72 Asia Singapore Pte. Ltd. owned about 0.07% of Enanta Pharmaceuticals worth $186,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ENTA. Vanguard Group Inc. lifted its holdings in Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after buying an additional 134,292 shares in the last quarter. Farallon Capital Management LLC lifted its stake in shares of Enanta Pharmaceuticals by 3.5% in the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock worth $36,579,000 after acquiring an additional 70,000 shares in the last quarter. Pennant Investors LP purchased a new position in Enanta Pharmaceuticals in the fourth quarter valued at about $330,000. Cubist Systematic Strategies LLC grew its stake in Enanta Pharmaceuticals by 65.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after purchasing an additional 18,003 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Enanta Pharmaceuticals by 1.3% during the 1st quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock worth $14,906,000 after purchasing an additional 10,952 shares during the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Enanta Pharmaceuticals

In other news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total transaction of $64,785.93. Following the sale, the insider now directly owns 23,988 shares in the company, valued at approximately $361,499.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Scott T. Rottinghaus sold 4,299 shares of the company’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the transaction, the insider now owns 23,988 shares in the company, valued at $361,499.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Scott T. Rottinghaus sold 5,375 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the sale, the insider now directly owns 21,717 shares in the company, valued at approximately $370,926.36. The disclosure for this sale can be found here. 13.64% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ENTA has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, August 6th. JPMorgan Chase & Co. decreased their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. Finally, Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $19.00.

Enanta Pharmaceuticals Price Performance

Enanta Pharmaceuticals stock opened at $10.47 on Friday. Enanta Pharmaceuticals, Inc. has a 12 month low of $8.08 and a 12 month high of $17.80. The company has a fifty day moving average price of $12.87 and a two-hundred day moving average price of $13.50. The company has a market cap of $221.74 million, a PE ratio of -1.68 and a beta of 0.59.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The business had revenue of $17.97 million during the quarter, compared to analyst estimates of $17.44 million. During the same period in the previous year, the business posted ($1.27) EPS. The company’s quarterly revenue was down 4.9% on a year-over-year basis. Equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.3 earnings per share for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.